Kazia Therapeutics Limite... (KZIA)
1.51
0.01 (0.67%)
At close: Jan 14, 2025, 3:59 PM
1.55
2.65%
After-hours Jan 14, 2025, 04:44 PM EST
undefined% (undefined)
| Bid | 1.44 |
| Market Cap | 5.03M |
| Revenue (ttm) | - |
| Net Income (ttm) | - |
| EPS (ttm) | -6.25 |
| PE Ratio (ttm) | -0.24 |
| Forward PE | n/a |
| Analyst | Buy |
| Ask | 1.69 |
| Volume | 41,255 |
| Avg. Volume (20D) | 141,829 |
| Open | 1.51 |
| Previous Close | 1.50 |
| Day's Range | 1.47 - 1.59 |
| 52-Week Range | 1.42 - 15.80 |
| Beta | undefined |
About KZIA
Kazia Therapeutics Limited, an oncology-focused biotechnology company, develops anti-cancer drugs. Its lead development candidate is Paxalisib, a small molecule, brain-penetrant inhibitor of the PI3K/Akt/mTor pathway, which is developed as a potential therapy for glioblastoma. It is also developing EVT801, an investigational new drug for various forms of cancer. The company was formerly known as Novogen Limited and changed its name to Kazia Thera...
Industry Biotechnology
Sector Healthcare
IPO Date Jan 6, 1999
Employees 9
Stock Exchange NASDAQ
Ticker Symbol KZIA
Analyst Forecast
According to 1 analyst ratings, the average rating for KZIA stock is "Buy." The 12-month stock price forecast is $20, which is an increase of 1224.50% from the latest price.
Buy 100.00%
Hold 0.00%
Sell 0.00%
2 weeks ago ·
Source
-42.9%
Kazia Therapeutics shares are trading lower after ...
Unlock content with
Pro Subscription
2 months ago ·
Source
+19.2%
Kazia Therapeutics shares are trading higher after the company announced it was granted a type C meeting with the FDA to discuss potential next steps for Paxalisib in the treatment of newly diagnosed Glioblastoma Multiforme.
